Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium
- 1 February 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (2), 382-390
- https://doi.org/10.1158/1535-7163.mct-05-0303
Abstract
Epidemiologic studies implicate inflammatory stimuli in the development of ovarian cancer. The proinflammatory cytokine tumor necrosis factor α (TNF-α) and both its receptors (TNFRI and TNFRII) are expressed in biopsies of this malignancy. Here, we tested the hypothesis that TNF-α is a regulator of the proinflammatory microenvironment of ovarian cancer. A cancer profiling array showed higher expression of TNF-α in ovarian tumors compared with normal ovarian tissue, and cultured ovarian cancer cells expressed up to 1,000 times more TNF-α mRNA than cultured normal ovarian surface epithelial cells; TNF-α protein was only detected in the supernatant of tumor cell cultures. Treatment with TNF-α induced TNF-α mRNA via TNFRI in both malignant and normal cells with evidence for enhanced TNF-α mRNA stability in tumor cells. TNF-α induced TNF-α protein in an autocrine fashion in tumor but not in normal ovarian surface epithelial cells. The TNF-α neutralizing antibody infliximab reduced the constitutive levels of TNF-α mRNA in tumor cell lines capable of autocrine TNF-α production. Apart from TNF-α mRNA expression, several other proinflammatory cytokines were constitutively expressed in malignant and normal ovarian surface epithelial cells, including interleukin (IL)-1α, IL-6, CCL2, CXCL8, and M-CSF. TNF-α treatment further induced these cytokines with de novo transcription of IL-6 mRNA contrasting with the increased stability of CCL2 mRNA. RNA interference directed against TNF-α was highly effective in abolishing constitutive IL-6 production by ovarian tumor cells. In summary, we show that TNF-α is differentially regulated in ovarian cancer cells compared with untransformed cells and modulates production of several cytokines that may promote ovarian tumorigenesis. Infliximab treatment may have a role in suppressing the TNF-α-driven inflammatory response associated with ovarian cancer. [Mol Cancer Ther 2006;5(2):382-90]Keywords
This publication has 32 references indexed in Scilit:
- Smoldering and polarized inflammation in the initiation and promotion of malignant diseaseCancer Cell, 2005
- NF-κB functions as a tumour promoter in inflammation-associated cancerNature, 2004
- Cytokines in cancer pathogenesis and cancer therapyNature Reviews Cancer, 2004
- von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA ArraysMolecular and Cellular Biology, 2003
- Inflammation and cancerNature, 2002
- Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomasActa Obstetricia et Gynecologica Scandinavica, 2000
- CorrespondenceEuropean Journal Of Cancer, 1998
- The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer.Journal of Clinical Investigation, 1995
- Secretion of Bioactive Interleukin-1, Interleukin-6, and Colony-Stimulating Factors by Human Ovarian Surface Epithelium1Biology of Reproduction, 1993
- Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression.Journal of Clinical Investigation, 1993